These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 27866195

  • 1. Comparison of Telbivudine and Entecavir Therapy on Nephritic Function and Drug Resistance in Patients with Hepatitis B Virus-Related Compensated Cirrhosis.
    Shen H, Ding F, Wang Z, Sun F, Yu Y, Zhou J, Xu W, Ni J, Wang J, Yang Y.
    Cell Physiol Biochem; 2016; 40(1-2):370-378. PubMed ID: 27866195
    [Abstract] [Full Text] [Related]

  • 2. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
    Law ST, Lee MK, Li KK, Mok CK.
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
    [Abstract] [Full Text] [Related]

  • 3. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
    Law ST, Lee MK, Lee AS, Tung Y, Li KK.
    J Dig Dis; 2016 May; 17(5):325-33. PubMed ID: 27085094
    [Abstract] [Full Text] [Related]

  • 4. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ.
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
    Cai S, Cao J, Yu T, Xia M, Peng J.
    Medicine (Baltimore); 2017 Jun; 96(22):e7021. PubMed ID: 28562554
    [Abstract] [Full Text] [Related]

  • 7. Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis.
    Tsai MC, Yu HC, Hung CH, Lee CM, Chiu KW, Lin MT, Tseng PL, Chang KC, Yen YH, Chen CH, Hu TH.
    J Gastroenterol Hepatol; 2014 Mar; 29(3):568-75. PubMed ID: 24716215
    [Abstract] [Full Text] [Related]

  • 8. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
    Kim DH, Choi JW, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Shin SY, Lee CK.
    Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
    [Abstract] [Full Text] [Related]

  • 9. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
    Su QM, Ye XG.
    World J Gastroenterol; 2012 Nov 21; 18(43):6290-301. PubMed ID: 23180951
    [Abstract] [Full Text] [Related]

  • 10. Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients.
    Lin YS, Shih SC, Wang HY, Lin CC, Chang CW, Chen MJ.
    BMC Gastroenterol; 2017 Jan 31; 17(1):22. PubMed ID: 28137301
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
    Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.
    Liver Int; 2015 Mar 31; 35(3):860-9. PubMed ID: 24905912
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
    Wang GL, Liu Y, Qiu P, Zhou SF, Xu LF, Wen P, Wen JB, Xiao XZ.
    Eur Rev Med Pharmacol Sci; 2016 Mar 31; 20(5):866-72. PubMed ID: 27010143
    [Abstract] [Full Text] [Related]

  • 13. Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis.
    Wu X, Cai S, Li Z, Zheng C, Xue X, Zeng J, Peng J.
    Virol J; 2016 Apr 09; 13():64. PubMed ID: 27062520
    [Abstract] [Full Text] [Related]

  • 14. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy.
    Liu B, Shen B, Mei M, Li L, Wang X, Zhao H.
    Ther Apher Dial; 2020 Feb 09; 24(1):56-63. PubMed ID: 31090170
    [Abstract] [Full Text] [Related]

  • 15. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
    Lee M, Oh S, Lee HJ, Yeum TS, Lee JH, Yu SJ, Kim HY, Yoon JH, Lee HS, Kim YJ.
    J Viral Hepat; 2014 Dec 09; 21(12):873-81. PubMed ID: 24351112
    [Abstract] [Full Text] [Related]

  • 16. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH.
    Clin Exp Med; 2017 May 09; 17(2):233-241. PubMed ID: 27094312
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B.
    Lee S, Park JY, Song K, Kim DY, Kim BK, Kim SU, Ku HJ, Han KH, Ahn SH.
    Gut Liver; 2015 Nov 23; 9(6):776-83. PubMed ID: 25963085
    [Abstract] [Full Text] [Related]

  • 18. Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
    Yang X, Li J, Zhou L, Liu J, Wang J, Lu W.
    Eur J Gastroenterol Hepatol; 2014 Apr 23; 26(4):396-403. PubMed ID: 24569820
    [Abstract] [Full Text] [Related]

  • 19. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification.
    Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK.
    Yonsei Med J; 2018 May 23; 59(3):383-388. PubMed ID: 29611400
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.